Autoinjectors Market Size is projected to reach USD 4.61 Billion by 2030, growing at a CAGR of 18.23%: Straits Research

New York, United States, Aug. 10, 2022 (GLOBE NEWSWIRE) -- An autoinjector is a prefilled syringe with a spring-loaded needle that automatically inserts the needle at the right injection location. The study only analyzes income produced by autoinjector device sales; it does not include money earned by medicine sales. Furthermore, it excludes money earned by fees paid to doctors or healthcare practitioners who recommend various treatments or testing.
Key Insights

• The disposable autoinjectors segment was the highest contributor growing at a CAGR of 18.6% during the forecast period.
• The anaphylaxis segment was the highest contributor to the market growth. It is predicted to grow at at a CAGR of 18.23% during the forecast period.
• The home care settings segment was the highest contributor to the market growth and it is expected to grow at a CAGR of 18.3% during the forecast period.
• North America dominated the global market. It is registering a CAGR of 17.9% during the forecast period. The market in Asia-Pacific is estimated to grow at a significant CAGR of 18.7%.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/autoinjector-market/request-sample

Rise Prevalence of Anaphylaxis Increase the Demand for Autoinjectors
Anaphylaxis is a severe allergic reaction that frequently causes swelling, low blood pressure, and, in severe cases, shocks. Allergy is the most frequent chronic condition in Europe, according to Allergy UK 2016. Furthermore, according to the World Allergy Organization (WAO), the allergy prevalence population in nations ranged between 10% and 40% in 2016. More than 150 million Europeans suffer from chronic allergy disorders, with half of the EU population expected to be afflicted by 2025.
Many drugs are now delivered at home to decrease the strain on healthcare providers and patients. Furthermore, innovative drug administration techniques that match the demands of patients, such as self injectors and autoinjectors, are increasingly being employed to administer biologics for the treatment of anaphylaxis, which is projected to drive market expansion.
Demand for biosimilars has skyrocketed as a result of lower prices and equivalent efficacy and quality to branded drugs. Many biologics patents are about to expire, boosting the need for biosimilars. These biosimilars offer a low-cost alternative, boosting market pricing pressure and competitiveness. Specialty doctors and nurse practitioners recognize the efficacy and therapeutic outcomes of biosimilars. Biosimilars are being looked at by both payers and patients as a method to reduce costs and give better treatment alternatives.
Furthermore, biosimilars and generics are preferred by governments and insurance companies. Biosimilars are an appealing alternative to branded biologics due to their low cost, and cost savings may drive insurance companies to switch to biosimilars.
In March 2019, Eli Lilly launched a generic version of its trademark insulin at half the price. Furthermore, CVS Caremark, a CVS Health prescription benefit management organization, has substituted branded injectable drugs such as EpiPen (by Mylan) and Copaxone (by Teva) with the generic version of Glatiramer Acetate (Autoinjector) by Mylan in the United States. As many injectables used to treat chronic diseases are biologics, patent expirations and increased support from governments and insurance providers provide an opportunity for market growth.

Report Scope       

Buy Now Full Report @ https://straitsresearch.com/buy-now/autoinjector-market

Impact of COVID-19
The COVID-19 pandemic has resulted in a global healthcare crisis, resulting in a shift in healthcare delivery in the majority of locations. Most unrelated procedures were postponed in the first half of 2020 to decrease the virus's spread and lessen the load on healthcare infrastructure. According to Indiana University researchers, healthcare visits decreased by 40% in the first six weeks of the epidemic in the United States, from early March to mid-April.
Following the loosening of restrictions, there has been a general drop in the number of persons delaying seeking care and treatment at healthcare institutions. Furthermore, the slowdown in clinical trial recruitment has delayed the introduction of new therapies. These issues may have a negative impact on the autoinjectors market, especially with its use in healthcare institutions set to commence in early 2020.
However, due to a variety of reasons, the overall effect on autoinjectors is deemed beneficial, particularly over the projection period. In the biologics industry, there is a trend towards greater delivery volumes and less frequent dosage, which may be accomplished with appropriately tailored autoinjectors.
The COVID-19 epidemic has hastened the trend of self-injection, allowing patients to become more active and in control of their treatment. The tendency has promoted newer technologies in the autoinjectors market for enhanced injection speed regulation, injection site pain, and treat anxiety.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/autoinjector-market/request-sample

List of Key Players

• Amgen, Antares Pharm
• Becton Dickinson And Company (Bd),
• Eli Lilly and Company
• Johnson & Johnson
• Mylan
• Novartis AG
• Ypsomed AG

Global Autoinjectors Market: Segmentation
By Type

• Disposable autoinjectors
• Reusable autoinjectors

By Application

• Rheumatoid arthritis
• Anaphylaxis
• Multiple sclerosis
• Others

By End-User

• Home Care Settings
• Hospitals and Clinics

By Region

• North America
• Europe
• Asia-Pacific
• LAMEA

TABLE OF CONTENT
1          Introduction
1.1       Market Definition
1.2       Market Scope
2          Research Methodology
2.1       Primary Research
2.2       Research Methodology
2.3       Assumptions and Exclusions
2.4       Secondary Data Sources
3          Executive Summary
4          Autoinjectors Market Overview
4.1       Report Segmentation and Scope
4.2       Key Market Trends
4.2.1   Drivers
4.2.2   Restraints
4.2.3   Opportunities
4.3       Porter's Five Forces Analysis
4.3.1   Bargaining Power of Suppliers
4.3.2   Bargaining Power of Buyers
4.3.3   Threat of Substitution
4.3.4   Threat of New Entrants
4.3.5   Competitive Rivalry
4.4       Environment and Regulatory Landscape
4.5       Macro-Economic and Geopolitical Scenario
4.6       Parent Market Overview
4.7       Technology Landscape
5          Type Overview
5.1       Introduction
5.1.1   Market Size and Forecast
5.2       Disposable Autoinjectors
5.2.1   Market Size and Forecast
5.3       Reusable Autoinjector
5.3.1   Market Size and Forecast
6          Application Overview
6.1       Introduction
6.1.1   Market Size and Forecast
6.2       Rheumatoid Arthritis
6.2.1   Market Size and Forecast
6.3       Multiple Sclerosis
6.3.1   Market Size and Forecast
6.4       Diabetes
6.4.1   Market Size and Forecast
6.5       Anaphylaxis
6.5.1   Market Size and Forecast
6.6       Others
6.6.1   Market Size and Forecast
7          End-User Overview
7.1       Introduction
7.1.1   Market Size and Forecast
7.2       Home Care Settings
7.2.1   Market Size and Forecast
7.3       Hospitals & Clinics
7.3.1   Market Size and Forecast
7.4       Ambulatory Care Settings
7.4.1   Market Size and Forecast
8          Regional Overview
8.1       Introduction
8.1.1   Market Size and Forecast
8.2       Americas
8.2.1   Economic Overview
8.2.2   Market Scenario
8.2.3   North America
8.2.3.1            By Types
8.2.3.2            By Applications
8.2.3.3            By End User
8.2.4   The U.S.
8.2.4.1            By Types
8.2.4.2            By Applications
8.2.4.3            By End User
8.2.5   Canada
8.2.5.1            By Types
8.2.5.2            By Applications
8.2.5.3            By End User
8.2.6   South America
8.2.6.1            By Types
8.2.6.2            By Applications
8.2.6.3            By End User
8.3       Europe
8.3.1   Economic Overview
8.3.2   Market Scenario
8.3.3   Germany
8.3.3.1            By Types
8.3.3.2            By Applications
8.3.3.3            By End User
8.3.4   France
8.3.4.1            By Types
8.3.4.2            By Applications
8.3.4.3            By End User
8.3.5   The U.K.
8.3.5.1            By Types
8.3.5.2            By Applications
8.3.5.3            By End User
8.3.6   Italy
8.3.6.1            By Types
8.3.6.2            By Applications
8.3.6.3            By End User
8.3.7   Spain
8.3.7.1            By Types
8.3.7.2            By Applications
8.3.7.3            By End User
8.3.8   The Rest of Europe
8.3.8.1            By Types
8.3.8.2            By Applications
8.3.8.3            By End User
8.4       Asia-Pacific (APAC)
8.4.1   Economic Overview
8.4.2   Market Scenario
8.4.3   China
8.4.3.1            By Types
8.4.3.2            By Applications
8.4.3.3            By End User
8.4.4   Japan
8.4.4.1            By Types
8.4.4.2            By Applications
8.4.4.3            By End User
8.4.5   India
8.4.5.1            By Types
8.4.5.2            By Applications
8.4.5.3            By End User
8.4.6   Australia
8.4.6.1            By Types
8.4.6.2            By Applications
8.4.6.3            By End User
8.4.7   South Korea
8.4.7.1            By Types
8.4.7.2            By Applications
8.4.7.3            By End User
8.4.8   The Rest of APAC
8.4.8.1            By Types
8.4.8.2            By Applications
8.4.8.3            By End User
8.5       The Middle East and Africa
8.5.1   Economic Overview
8.5.2   Market Scenario
8.5.3   Middle East
8.5.3.1            By Types
8.5.3.2            By Applications
8.5.3.3            By End User
8.5.4   Africa
8.5.4.1            By Types
8.5.4.2            By Applications
8.5.4.3            By End User
9          Competitive Landscape — Manufacturers and Suppliers
9.1       Competition Dashboard
9.2       Market Share Analysis
9.3       Key Developments and Movements
9.4       Consolidated SWOT Analysis of Key Players
10        Company Profiles
10.1    AbbVie Inc
10.1.1 Business Overview
10.1.2 Financial Performance
10.1.3 Recent Developments
10.1.4 Application  Portfolio
10.2    Mylan
10.2.1 Business Overview
10.2.2 Financial Performance
10.2.3 Recent Developments
10.2.4 Application  Portfolio
10.3    Eli Lilly and Company
10.3.1 Business Overview
10.3.2 Financial Performance
10.3.3 Recent Developments
10.3.4 Application  Portfolio
10.4    Ypsomed
10.4.1 Business Overview
10.4.2 Financial Performance
10.4.3 Recent Developments
10.4.4 Application  Portfolio
10.5    Amgen
10.5.1 Business Overview
10.5.2 Financial Performance
10.5.3 Recent Developments
10.5.4 Application  Portfolio
10.6    Becton Dickson and Company
10.6.1 Business Overview
10.6.2 Financial Performance
10.6.3 Recent Developments
10.6.4 Application  Portfolio
10.7    GlaxoSmithKline plc
10.7.1 Business Overview
10.7.2 Financial Performance
10.7.3 Recent Developments
10.7.4 Application  Portfolio
10.8    Johnson & Johnson
10.8.1 Business Overview
10.8.2 Financial Performance
10.8.3 Recent Developments
10.8.4 Application  Portfolio
11        Conclusion and Recommendation
12        Acronyms and Abbreviations

Table of Content and Figure @ https://straitsresearch.com/report/autoinjector-market/toc

Market News

• In November 2017, Amgen launched ENBREL Mini Single-Dose Prefilled Cartridge along with AutoTocuhReusableAutoinjector. ENBREL is used to treat patients with arthritis and moderate-to-severe plaque psoriasis (PsO). The Mini ENBREL with AutoTouch is available in the U.S.
• In December 2021, Antares Pharma announced the divestiture of Otrexup injection for treating rheumatoid arthritis to a subsidiary of AssertioHldings, Inc, a pharmaceutical company.
• In August 2018, Antares Pharma announced an agreement with Pfizer to develop a combination drug-device. This utilizes Antares QuickShot with an undisclosed Pfizer drug, and Antares Pharma receives royalties on net sales on the combination product.
• In August 2018, Antares Pharma received FDA approval for Teva's epinephrine auto-injector drug-device combination product, which is used to treat severe allergic reactions,

News Media

Autoinjector Market to Grow at a Healthy CAGR of 14.4%

The Tangential Flow Filtration Market to Benefit from the Widescale Adoption of Single-Use Technologies

Have a Look at the Related Research Report
Diabetes Care Devices Market: Information by Monitoring Devices (Self-monitoring Blood Glucose Device), Management Devices (Insulin Syringes, Jet Injectors), and Region — Forecast till 2030
Needle Free Injection Systems Market: Information by Product (Prefilled, Fillable), Technology, Usability, Type of Medication, Delivery Site, and Regional Outlook - Forecast Till 2026
Plastic Injection Molding Market: Information by Raw Material (Polypropylene, Polystyrene, Polyethylene, Polyamide), Application (Packaging, Electronics), and Region — Forecast till 2030

About Straits Research Pvt. Ltd.
StraitsResearch is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:
Phone: +1 646 480 7505 (the U.S.)
+91 8087085354 (APAC)             
+44 208 068 9665 (the U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter